You are here

Global Neoantigen Targeted Therapies Market 2019-2030: Marketed and Development Pipeline, Pipeline Analysis, List of Drug Developers

DUBLIN, Aug. 6, 2019 /PRNewswire/ -- The "Neoantigen Targeted Therapies Market, 2019-2030" report has been added to ResearchAndMarkets.com's offering.

The Neoantigen Targeted Therapies Market, 2019-2030 report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.

One of the key objectives of the report was to estimate the existing market size and the future opportunity for neoantigen targeted therapies, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption of neoantigen targeted therapies and the likely selling price of such therapeutic products, we have provided informed estimates on the evolution of the market for the period 2019-2030.

The report also features the likely distribution of the current and forecasted opportunity across:

  • [A] different target indications (bone and cartilage cancer, colorectal cancer, head and neck cancer, renal carcinoma, hepatocellular carcinoma, lung cancer, gynecological cancer and others)
  • [B] type of treatment (personalized and off-the-shelf)
  • [C] type of immunotherapy (dendritic cell vaccine, DNA / RNA-based vaccine, protein / peptide-based vaccine and TIL-based therapy)
  • [D] route of administration (intradermal, intravenous, subcutaneous, and others)
  • [E] key geographical regions (US, EU5 and rest of the world).

In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

In addition to other elements, the study includes:

  • A detailed assessment of the current market landscape, providing information on drug developer(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, type of molecule (small molecule and biologic), type of treatment (personalized and off-the-shelf), type of therapy (monotherapy and combination therapy), type of immunotherapy, target indication, line of treatment, and route of administration of the drugs / therapies that are being developed for the treatment of cancer.
  • Detailed profiles of developers of neoantigen targeted therapies (shortlisted on the basis of the number of pipeline products), featuring an overview of the company, its financial information (if available), a detailed description of its product portfolio and recent collaborations. In addition, each profile includes an informed future outlook.
  • A detailed publication analysis of close to 300 peer-reviewed, scientific articles published during the period 2015-2019 (till February), highlighting the research focus within the industry. It also highlights the key trends observed across the publications, including information on target disease indications, affiliated cancer immunotherapies, and analysis based on various relevant parameters, such as study type (review article, research article and meta-analysis), year of publication, and most popular journals (in terms of number of articles published in the given time period) within this domain.
  • An in-depth analysis of the various patents that have been filed/granted related to neoantigens until April 2019. It includes information on key parameters, such as patent type, publication year, issuing authority, assigned CPC symbol, emerging focus areas and leading industry / academic players (in terms of size of intellectual property portfolio).
  • An analysis of the various partnerships pertaining to neoantigen targeting therapies, which have been established till March 2019, based on various parameters, such as the type of partnership, year of partnership, target disease indications, type of immunotherapy and the most active players.
  • An analysis of the investments made, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are focused on developing neoantigen targeted therapies.

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Concept of Immunotherapy
3.3. History of Cancer Immunotherapy
3.4. Limitations of Cancer Immunotherapy
3.5. Targeting Tumor-Specific Neoantigens
3.5.1. Types of Neoantigens
3.5.2. Role of Neoantigens in Cancer Immunotherapy
3.5.3. Neoantigen Targeted Therapies
3.5.3.1. Identification and Selection of Neoantigens
3.5.3.2. Delivery of Neoantigen Targeted Therapies
3.6. Key Challenges and Future Perspectives

4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Neoantigen Targeted Therapies: Marketed and Development Pipeline
4.3. Neoantigen Targeted Therapies: Pipeline Analysis
4.4. Neoantigen Targeted Therapies: List of Drug Developers
4.5. Grid Analysis: Analysis by Target Disease Indication, Company Size and Location

5. COMPANY PROFILES: NEOANTIGEN TARGETED THERAPIES
5.1. Chapter Overview
5.2. Bavarian Nordic
5.3. Genocea Biosciences
5.4. Gradalis
5.5. Immunicum
5.6. Immunovative Therapies
5.7. Iovance Biotherapeutics
5.8. MediGene
5.9. Neon Therapeutics

6. PUBLICATION ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.3. Neoantigen Targeted Therapies: List of Publications

7. PATENT ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Neoantigen Targeted Therapies: Patent Analysis
7.4. Neoantigen Targeted Therapies: Patent Benchmarking Analysis
7.5. Neoantigen Targeted Therapies: Patent Valuation Analysis

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Neoantigen Targeted Therapies: List of Partnerships and Collaborations

9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. Neoantigen Targeted Therapies: Funding and Investment Analysis
9.4. Concluding Remarks

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1 Chapter Overview
10.2. Key Assumptions and Forecast Methodology
10.3. Global Neoantigen Targeted Therapies Market, 2019-2030

11. CONCLUDING REMARKS

12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. AIVITA Biomedical
12.3. BioLineRx
12.3. VAXIMM

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

  • 5AM Ventures
  • AbbVie Ventures
  • Abingworth
  • Abu Dhabi Investment Authority
  • Accelerate NY Seed Fund
  • Accelovance
  • Access Industries
  • Achilles Therapeutics
  • Adage Capital Management
  • Adaptive Biotechnologies
  • Aduro Biotech
  • Advaxis
  • Agalimmune
  • Agenus
  • Ageo Central General Hospital
  • Agreen Biotech
  • Aisling Capital
  • AIVITA Biomedical
  • Albion Capital
  • Alexandria Venture Investments
  • Alexion Pharmaceuticals
  • Allscripts
  • AMAL Therapeutics
  • Amgen Ventures
  • Andera Partners
  • Apexigen
  • Arbutus Biopharma
  • ARCH Venture Partners
  • Arcus Biosciences
  • ArrowMark Partners
  • Asia Genomics
  • Astellas Pharma
  • AstraZeneca
  • AT Impf
  • Atlas Venture
  • Baillie Gifford
  • Bain Capital Life Sciences
  • Bavarian Nordic
  • BB Biotech
  • Beth Israel Deaconess Medical Center
  • BGI Americas
  • Bill & Melinda Gates Foundation
  • BioClub
  • BioLife Solutions
  • BioLineRx
  • BioMedPartners
  • BioNJ
  • BioNTech
  • BlackBerry Partners Fund
  • Blackstone
  • bluebird bio
  • Boehringer Ingelheim Venture Fund
  • Bpifrance
  • BrightPath Biotherapeutics
  • Bristol-Myers Squibb
  • Broad Institute
  • Broadfin Capital
  • Button Capital
  • BVF Partners
  • Caladrius Biosciences
  • California Technology Ventures
  • Canaan Investment
  • Cancer Prevention and Research Institute of Texas
  • Cancer Research Technology
  • Casdin Capital
  • Catalent
  • Celgene
  • Cellular Biomedicine
  • Charles River Laboratories
  • Chartwave
  • Children's Hospital of Orange County
  • China Medical System
  • Clal Biotechnology Industries
  • Clarus Ventures
  • Clough Capital Partners
  • Comecer
  • Cormorant Asset Management
  • CRISPR Therapeutics
  • Cryoport
  • CTI Life Sciences
  • CureVac
  • CyTIX
  • Cytovance Biologics
  • Dana-Farber Cancer Institute
  • DATUM
  • Decheng Capital
  • dievini Hopp Biotech
  • Droia Oncology Ventures
  • EcoR1 Capital
  • EDBI
  • Effimune
  • EIC SME Instrument
  • Eli Lilly
  • ELMA Investments
  • EMD Millipore
  • EpiVax Oncology
  • EUFETS
  • European Investment Bank
  • Evaxion Biotech
  • F-Prime Capital
  • Fidelity Investments
  • Flow Pharma
  • Forbion
  • Foresite Capital
  • Franklin Advisers
  • Frazier Healthcare Partners
  • Genentech
  • Geneos Therapeutics
  • Genocea Biosciences
  • Georgetown University
  • GlobeImmune
  • Google Ventures
  • Gradalis
  • Grey Wolf Therapeutics
  • Gritstone Oncology
  • Hangzhou Neoantigen Therapeutics
  • Heat Biologics
  • Helmholtz Zentrum Mnchen
  • Helsinn Group
  • HengRui YuanZheng Biotechnology
  • Hercules Capital
  • High-Tech Grnderfonds
  • Hillhouse Capital Group
  • Icahn School of Medicine at Mount Sinai
  • IDG Capital
  • Immatics
  • Immune Design
  • ImmuNext
  • Immunicum
  • Immunomic Therapeutics
  • Immunovative Therapies
  • IMV Technologies
  • Infinity Pharmaceuticals
  • Innovate UK
  • Innovation Fund Denmark
  • Inovio Pharmaceuticals
  • Institut Mrieux
  • Intrexon
  • Investsud
  • Iovance Biotherapeutics
  • ISA Pharmaceuticals
  • Janssen Pharmaceuticals
  • Janus Capital Management
  • Janus Henderson Investors
  • Jennison Associates
  • Johnson & Johnson Development
  • Kanagawa Cancer Center
  • Karolinska University Hospital
  • Keiretsu Forum
  • Khoen Ken Medical Center
  • Kuwait Investment Authority
  • La Jolla Institute for Allergy and Immunology
  • Leerink Partners
  • Leiden University Medical Center
  • Level One Partners
  • Likang Life Sciences
  • Lilly Asia Ventures
  • LSP
  • Massachusetts General Hospital
  • MaSTherCell
  • Mateon Therapeutics
  • Max Delbrck Center for Molecular Medicine in the Helmholtz Association
  • MD Anderson Cancer Center
  • Medigene
  • MedImmune
  • Meir Medical Center
  • Memorial Sloan Kettering Cancer Center
  • Merck
  • Meusinvest
  • Mie University
  • Miller Value Partners
  • Miracle Light Incubator
  • Moderna Therapeutics
  • Moffitt Cancer Center
  • Morningside Group
  • MSD Partners
  • NantBioScience
  • NantCell
  • NantWorks
  • Natera
  • National Institutes of Health
  • Natixis
  • NEC
  • Nektar Therapeutics
  • Neon Therapeutics
  • NeoPhore
  • Netherlands Cancer Institute
  • NexImmune
  • Nextech Invest
  • NextWavebio
  • Norwegian Cancer Society
  • Nouscom
  • Novartis
  • Novartis Institutes for BioMedical Research
  • Ohio State University Comprehensive Cancer Center
  • Omega Funds
  • Omeros
  • OncoImmunity
  • Oncos Therapeutics
  • OncoSec Medical
  • Oncotest-Teva
  • OPKO Health
  • OrbiMed Advisors
  • ORYX Translational Medicine
  • OSE Immunotherapeutics
  • PACT Pharma
  • Parker Institute for Cancer Immunotherapy
  • Partner Fund Management
  • Paulson Capital
  • PCI Biotech
  • PDC*line Pharma
  • Pelican Therapeutics
  • Perceptive Advisors
  • Persimmune
  • Pfizer Ventures
  • PharmaCell
  • Pharmaceutical Product Development
  • Pharmstandard International
  • Phio Pharmaceuticals
  • PhosImmune
  • Phyton Biotech
  • Pictet
  • PolyBioCept
  • Pontifax
  • Precigen
  • Precision BioLogic
  • ProBioGen
  • Quogue Capital
  • RA Capital Management
  • Redmile Group
  • Regeneron Pharmaceuticals
  • Replimune
  • Roche
  • RTW Investments
  • Ruffer
  • Rutgers Cancer Institute
  • Sailing Capital
  • Sanquin Blood Supply Foundation
  • Sant Ventures
  • Schroder Adveq
  • SciVac Therapeutics
  • Sectoral Asset Management
  • Sequoia Capital China
  • SGI-DNA
  • Shenzhen Yuce Biotechnology
  • Siemens
  • SIGMA Group
  • Sixth Element Capital
  • Sorgente
  • Spinventure
  • Square 1 Bank
  • Stand Up To Cancer
  • Stanford University
  • Stemirna Therapeutics
  • Structured Immunity
  • Struengmann Family Office
  • Sygnature Discovery
  • Syncona
  • SYZ Cell Therapy
  • T. Rowe Price Associates
  • Taiho Pharmaceutical
  • Taiho Ventures
  • Targovax
  • tella
  • Texas Oncology
  • The Column Group
  • The Francis Crick Institute
  • The Invus Group
  • The Research Council of Norway
  • Third Rock Ventures
  • ThorgeneNeo
  • TrakCel
  • Transformational Healthcare Venture Capital
  • Transgene
  • Trianta Immunotherapies
  • Trinitas Capital Management
  • Turnstone Biologics
  • UConn Health
  • University College London
  • University Hospital Southampton NHS Foundation Trust
  • University of Colorado
  • University of Lausanne
  • University of North Carolina
  • University of Washington
  • Vaccibody
  • Vaxil Bio therapeutics
  • VAXIMM
  • VAXON Biotech
  • VBI Vaccines
  • Vedantra Pharmaceuticals
  • Verizon
  • Versant Ventures
  • Viking Global Investors
  • Wallonia Biotech Coaching
  • Washington University School of Medicine
  • Wellington Partners
  • WhiteRock Capital Partners
  • Wu Capital Group
  • Wuhan Dangdai Science & Technology Industries
  • WuXi AppTec
  • Yale Cancer Center
  • Zelluna Immunotherapy
  • Ziopharm Oncology

For more information about this report visit https://www.researchandmarkets.com/r/jozcmn

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


Cision View original content:http://www.prnewswire.com/news-releases/global-neoantigen-targeted-therapies-market-2019-2030-marketed-and-development-pipeline-pipeline-analysis-list-of-drug-developers-300897075.html

SOURCE Research and Markets